Results from Three Pivotal Phase III Efficacy and Safety Trials (Studies RVL-1201-201, 202 and 203) to Be Presented at Multiple Global Congresses BRIDGEWATER, N.J., Sept. 18, 2019 (GLOBE NEWSWIRE) — Vertical Pharmaceuticals, LLC (a subsidiary of Osmotica...
Company’s insulin-based Imotope(TM) IMCY-0098 shows excellent safety profile and promising clinical trends LIÈGE, BELGIUM / ACCESSWIRE / September 18, 2019 / Imcyse, a clinical-stage company developing active and specific immunotherapeutics for the treatment and...
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced dosing of the first healthy volunteer in the...
DEVOTE trial to evaluate safety and even greater efficacy of a higher dose of SPINRAZA in the treatment of SMA; well-established safety profile supports exploration of potential benefits Long-term data from the SHINE study demonstrate improvements in or stabilization...
– Study Achieves a 44% Median Seizure Reduction in Focal Impaired Awareness (Complex Partial) and Convulsive Seizures in DEE Patients by Month Two; Reductions were Sustained through Month Six of Treatment with Zygel – – At Least 42% of these Patients...
DEVOTE trial to evaluate safety and even greater efficacy of a higher dose of SPINRAZA in the treatment of SMA; well-established safety profile supports exploration of potential benefits Long-term data from the SHINE study demonstrate improvements in or stabilization...
Email
Text